WO2008118013A3 - Targeted intracellular delivery of antiviral agents - Google Patents

Targeted intracellular delivery of antiviral agents Download PDF

Info

Publication number
WO2008118013A3
WO2008118013A3 PCT/NL2008/050166 NL2008050166W WO2008118013A3 WO 2008118013 A3 WO2008118013 A3 WO 2008118013A3 NL 2008050166 W NL2008050166 W NL 2008050166W WO 2008118013 A3 WO2008118013 A3 WO 2008118013A3
Authority
WO
WIPO (PCT)
Prior art keywords
antiviral compounds
organs
tissues
cells
drug delivery
Prior art date
Application number
PCT/NL2008/050166
Other languages
French (fr)
Other versions
WO2008118013A2 (en
Inventor
Pieter Jaap Gaillard
Original Assignee
To Bbb Holding B V
Pieter Jaap Gaillard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by To Bbb Holding B V, Pieter Jaap Gaillard filed Critical To Bbb Holding B V
Priority to US12/532,788 priority Critical patent/US20100129437A1/en
Priority to EP08723917A priority patent/EP2125024B1/en
Publication of WO2008118013A2 publication Critical patent/WO2008118013A2/en
Publication of WO2008118013A3 publication Critical patent/WO2008118013A3/en
Priority to US13/875,729 priority patent/US20130216612A1/en
Priority to US14/692,422 priority patent/US20150290234A1/en
Priority to US16/914,567 priority patent/US20200390794A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to methods of targeted drug delivery of antiviral compounds, including, chemical agents (like nucleoside analogs or protease inhibitors) and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of antiviral compounds to intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (CNS), into and across the blood-brain barrier, by targeting to internalizing uptake receptors present on these cells, tissues and organs. Thereto, the antiviral compounds, or the pharmaceutical acceptable carrier thereof, are conjugated to ligands that facilitate the specific binding to and internalization by these receptors.
PCT/NL2008/050166 2007-03-23 2008-03-21 Targeted intracellular delivery of antiviral agents WO2008118013A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/532,788 US20100129437A1 (en) 2007-03-23 2008-03-21 Targeted intracellular delivery of antiviral agents
EP08723917A EP2125024B1 (en) 2007-03-23 2008-03-21 Targeted intracellular delivery of antiviral agents
US13/875,729 US20130216612A1 (en) 2007-03-23 2013-05-02 Targeted intracellular delivery of antiviral agents
US14/692,422 US20150290234A1 (en) 2007-03-23 2015-04-21 Targeted intracellular delivery of antiviral agents
US16/914,567 US20200390794A1 (en) 2007-03-23 2020-06-29 Targeted intracellular delivery of antiviral agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90717607P 2007-03-23 2007-03-23
US60/907,176 2007-03-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/532,788 A-371-Of-International US20100129437A1 (en) 2007-03-23 2008-03-21 Targeted intracellular delivery of antiviral agents
US13/875,729 Division US20130216612A1 (en) 2007-03-23 2013-05-02 Targeted intracellular delivery of antiviral agents

Publications (2)

Publication Number Publication Date
WO2008118013A2 WO2008118013A2 (en) 2008-10-02
WO2008118013A3 true WO2008118013A3 (en) 2009-02-19

Family

ID=39485128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2008/050166 WO2008118013A2 (en) 2007-03-23 2008-03-21 Targeted intracellular delivery of antiviral agents

Country Status (11)

Country Link
US (4) US20100129437A1 (en)
EP (2) EP2308514B1 (en)
CY (1) CY1114116T1 (en)
DK (1) DK2308514T3 (en)
ES (1) ES2426684T3 (en)
HR (1) HRP20130547T1 (en)
PL (1) PL2308514T3 (en)
PT (1) PT2308514E (en)
SI (1) SI2308514T1 (en)
TW (2) TWI537005B (en)
WO (1) WO2008118013A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102172348A (en) * 2011-02-12 2011-09-07 李春娟 Solid oseltamivir phosphate medicinal composition

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2249838T3 (en) * 1997-07-11 2006-04-01 The Government Of The Usa As Represented By The Secretary Of The Depar. Of Health And Human Services CHEMERIC IMMUNOGENS SIMILAR TO EXOTOXIN A OF PSEUDOMONES.
US20050158296A1 (en) 2002-01-11 2005-07-21 Starr Christopher M. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
JP2008512445A (en) * 2004-09-09 2008-04-24 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム Use of liposomal glucocorticoids for the treatment of inflammatory conditions
US8642577B2 (en) 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008147526A1 (en) * 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
US8993542B2 (en) 2008-01-25 2015-03-31 Chimerix Inc. Methods of treating viral infections
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
EP2398500B1 (en) * 2009-02-20 2019-03-13 2-BBB Medicines B.V. Glutathione-based drug delivery system
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
US20130072458A1 (en) * 2009-10-30 2013-03-21 Chimerix, Inc. Methods of Treating Viral Associated Diseases
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
EP2534150B1 (en) 2010-02-12 2017-04-05 Chimerix, Inc. Methods of treating viral infection
WO2011130332A1 (en) * 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
AU2011248620B2 (en) 2010-04-26 2015-11-26 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
NZ724348A (en) 2010-11-30 2019-12-20 Genentech Inc Low affinity blood brain barrier receptor antibodies and uses therefor
US8877722B2 (en) * 2011-03-25 2014-11-04 Idera Pharmaceuticals, Inc. Compositions for inhibiting gene expression and uses thereof
CA2840221A1 (en) 2011-07-05 2013-01-10 Bioasis Technologies Inc. P97-antibody conjugates and methods of use
DE202012012956U1 (en) 2011-10-21 2014-10-16 Abbvie Inc. A combination of at least two direct-acting antiviral agents for use in the treatment of HCV, comprising ribavirin but not interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
UY34401A (en) 2011-10-21 2013-05-31 Abbvie Inc METHODS FOR HCV TREATMENT
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US9567391B2 (en) 2012-03-20 2017-02-14 Biogen Ma Inc. JCV neutralizing antibodies
WO2013142299A1 (en) * 2012-03-20 2013-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
US9932565B2 (en) 2012-07-31 2018-04-03 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
JP6302909B2 (en) 2012-08-18 2018-03-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Cell-permeable probes for sialidase identification and imaging
AU2014243816B2 (en) 2013-03-13 2019-01-31 Bioasis Technologies Inc. Fragments of p97 and uses thereof
WO2014201454A2 (en) * 2013-06-14 2014-12-18 University Of Notre Dame Dnazyme-nanoparticle conjugates and methods of use thereof
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
JP2016530294A (en) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Chimeric polynucleotide
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
US20160289303A1 (en) * 2013-11-15 2016-10-06 President And Fellows Of Harvard College Methods and compositions for the treatment of hcmv
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
ES2764973T3 (en) 2014-02-03 2020-06-05 Bioasis Technologies Inc P97 fusion proteins
DK3107562T3 (en) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-IDS FUSION PROTEIN
CN106415244B (en) 2014-03-27 2020-04-24 中央研究院 Reactive marker compounds and uses thereof
CN106413757B (en) * 2014-05-01 2022-01-14 比奥阿赛斯技术有限公司 P97-Polynucleotide conjugates
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
TWI717319B (en) 2014-05-27 2021-02-01 中央研究院 Fucosidase from bacteroides and methods using the same
EP3149036A4 (en) 2014-05-27 2017-12-27 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
EP4116329A1 (en) 2014-05-27 2023-01-11 Academia Sinica Anti-her2 glycoantibodies and uses thereof
TWI732738B (en) 2014-05-28 2021-07-11 中央研究院 Anti-tnf-alpha glycoantibodies and uses thereof
CA2960712A1 (en) 2014-09-08 2016-03-17 Academia Sinica Human inkt cell activation using glycolipids
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2972072A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
KR20170141774A (en) * 2015-04-29 2017-12-26 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 Therapeutic combinations of antiviral and anti-inflammatory therapeutic agents
CA3016170A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
CN110312532A (en) * 2016-12-19 2019-10-08 韩美药品株式会社 Brain targeting long-acting protein conjugate
US10842755B2 (en) 2018-03-23 2020-11-24 University Of South Carolina Nanoparticles for brain targeted drug delivery
CN111068069B (en) * 2018-10-18 2022-05-20 中国医学科学院药物研究所 Immune targeting functional liposome and preparation method and application thereof
CA3106735A1 (en) * 2019-05-21 2020-11-26 Universite Laval Crimean-congo hemorrhagic fever virus immunogenic compositions
NL2026569B1 (en) * 2020-09-29 2022-05-30 Crm Therapeutics B V Target mediated endocytotic drug delivery
NL2027601B1 (en) * 2021-02-19 2022-09-19 Crm Therapeutics B V Target mediated endocytotic drug delivery
WO2022069419A1 (en) 2020-09-29 2022-04-07 Crm Therapeutics B.V. Target mediated endocytotic drug delivery
WO2023049762A1 (en) * 2021-09-21 2023-03-30 Washington University Compositions and methods to modulate transfer across the blood-brain barrier
WO2023183628A2 (en) * 2022-03-25 2023-09-28 Judo Bio Inc. Targeted delivery
CN115252760A (en) * 2022-03-30 2022-11-01 厦门大学 Broad-spectrum anti-coronavirus preparation and preparation method thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965406A (en) * 1984-06-07 1999-10-12 Seragen, Inc. Recombinant DNAS encoding three-part hybrid proteins
WO2000037103A2 (en) * 1998-12-21 2000-06-29 Xavos Compounds for intracellular delivery of therapeutic moieties to nerve cells
WO2000046384A1 (en) * 1999-02-08 2000-08-10 University Of Maryland, Baltimore Nucleic acid uptake and release vehicle
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US20020098999A1 (en) * 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
US6613882B1 (en) * 1997-07-18 2003-09-02 Institut Curie And Centre National De La Recherche Scientifique Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest
WO2004069870A2 (en) * 2003-02-10 2004-08-19 To-Bbb Holding B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
WO2005054279A1 (en) * 2003-11-21 2005-06-16 Orthogen Ag Delivery peptides, their constructs with active agents and use
US20070141133A1 (en) * 2005-12-19 2007-06-21 Industrial Technology Research Institute Glutathione based delivery system

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PT1498427E (en) 1992-08-21 2010-03-22 Univ Bruxelles Immunoglobulins devoid of light chains
DK0698097T3 (en) 1993-04-29 2001-10-08 Unilever Nv Production of antibodies or (functionalized) fragments thereof derived from Camelidae heavy chain immunoglobulins
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
FR2708622B1 (en) 1993-08-02 1997-04-18 Raymond Hamers Recombinant vector containing a sequence of a structural lipoprotein gene for the expression of nucleotide sequences.
US5789543A (en) 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
ATE314097T1 (en) 1996-10-28 2006-01-15 Amersham Health As CONTRAST AGENTS
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
BR9907241A (en) 1998-01-26 2000-10-17 Unilever Nv Expression library, process for preparing the same, using an unimmunized source of nucleic acid sequences, and, processes for preparing antibody fragments and, for preparing an antibody
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
DK0978285T3 (en) 1998-08-07 2006-03-27 Curis Inc Stable pharmaceutical composition of hedgehog proteins and their use
ES2302391T3 (en) * 1998-12-18 2008-07-01 HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT COMPANY, LTD. PROCEDURE FOR ADMINISTRATION OF A COMPOSITE TO CELLS RESISTANT TO MULTI-PHARMACOS.
WO2000040968A1 (en) 1999-01-05 2000-07-13 Unilever Plc Binding of antibody fragments to solid supports
WO2000043507A1 (en) 1999-01-19 2000-07-27 Unilever Plc Method for producing antibody fragments
CN100434441C (en) 1999-04-22 2008-11-19 荷兰联合利华有限公司 Inhibition of viral infection using monovalent antigen-binding proteins
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
ATE440111T1 (en) 1999-11-29 2009-09-15 Bac Ip B V IMMOBILIZED ANTIGEN BINDING MOLECULES FROM A DOMAIN
EP1242460B1 (en) 1999-11-29 2006-10-18 Unilever Plc Immobilisation of proteins using a polypeptide segment
ATE428733T1 (en) 2000-03-14 2009-05-15 Unilever Nv VARIABLE DOMAIN OF THE HEAVY CHAIN OF AN ANTIBODY TO HUMAN NUTRITIONAL LIPASES AND THEIR USES
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
CN1315862C (en) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 Methods and compositions for treating flaviviruses and pestiviruses
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2002048193A2 (en) 2000-12-13 2002-06-20 Unilever N.V. Camelidae antibody arrays
EP1707571B1 (en) 2001-01-22 2011-09-28 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
DE10109897A1 (en) 2001-02-21 2002-11-07 Novosom Ag Optional cationic liposomes and their use
JP2004532022A (en) 2001-03-26 2004-10-21 サーナ・セラピューティクス・インコーポレイテッド Oligonucleotide-mediated inhibition of hepatitis B virus and hepatitis C virus replication
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (en) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy-chain antibody
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
US20050037358A1 (en) 2001-12-21 2005-02-17 Serge Muyldermans Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
ATE519774T1 (en) 2002-02-20 2011-08-15 Sirna Therapeutics Inc RNA DISRUPTION-MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION WITH SHORT INTERFERING NUCLEIC ACID (SINA)
CA2479530A1 (en) 2002-03-20 2003-10-02 Massachusetts Institute Of Technology Hiv therapeutic
EP1900753B1 (en) 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
AU2003300544A1 (en) 2003-01-09 2004-08-10 F. Hoffmann-La Roche Ag -modified nucleoside derivatives for treating flaviviridae infections
CA2512545C (en) 2003-01-10 2015-06-30 Karen Silence Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
WO2005019410A2 (en) 2003-04-25 2005-03-03 Intradigm Corporation Rnai agents for anti-sars coronavirus therapy
CN100481096C (en) * 2003-06-25 2009-04-22 美国西门子医疗解决公司 Automated regional myocardial assessment method for cardiac imaging
WO2005028650A2 (en) 2003-09-16 2005-03-31 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1689414A4 (en) 2003-12-04 2009-04-08 Univ South Florida Res Foundat Polynucleotides for reducing respiratory syncytial virus gene expression
WO2005076999A2 (en) 2004-02-05 2005-08-25 Intradigm Corporation Methods and compositions for combination rnai therapeutics
PL1574572T3 (en) 2004-03-09 2007-10-31 Prosensa Bv Compounds for hydrolysing ribonucleic acids (RNAs)
WO2005107742A1 (en) 2004-05-05 2005-11-17 Yale University Novel antiviral helioxanthin analogs
JP2008512500A (en) 2004-09-10 2008-04-24 ソマジェニックス インコーポレーティッド Small interfering RNA that efficiently inhibits viral gene expression and method of use thereof
EP1647595A1 (en) 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nucleic acids against viruses, in particular HIV
WO2006042418A1 (en) 2004-10-19 2006-04-27 Replicor Inc. Antiviral oligonucleotides
US20060089324A1 (en) 2004-10-22 2006-04-27 Sailen Barik RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
EP1817416A2 (en) 2004-11-05 2007-08-15 Intradigm Corporation Compositions for treating respiratory viral infections and their use
WO2006060774A2 (en) 2004-12-02 2006-06-08 Board Of Regents, The University Of Texas System Agents that inhibit flavivirus replication and uses thereof
EP1833966A2 (en) 2004-12-14 2007-09-19 National Institute of Immunology Dnazymes for inhibition of japanese encephalitis virus replication
EP1674104A1 (en) 2004-12-24 2006-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
JP5081630B2 (en) 2005-01-07 2012-11-28 アルナイラム ファーマシューティカルズ， インコーポレイテッド RNAi regulation of RSV and methods of its therapeutic use
US20080096839A1 (en) 2005-03-09 2008-04-24 Mogam Biotechnology Research Institute Small Interfering Rna and Pharmaceutical Composition for Treatment of Hepatitis B Comprising the Same
AU2006235364A1 (en) 2005-04-08 2006-10-19 Marina Biotech, Inc. RNAi therapeutic for respiratory virus infection
US20090221624A1 (en) 2005-05-06 2009-09-03 Olivo Paul D 4-aminoquinoline compounds for treating virus-related conditions
NZ563909A (en) 2005-05-13 2011-10-28 Virochem Pharma Inc Thiophene derivatives and their use for the treatment or prevention of flavivirus infections
KR100733186B1 (en) 2005-05-31 2007-06-27 재단법인 목암생명공학연구소 Small Interfering RNA specific for HCV and Therapeutic Agent for Hepatitis C Comprising the Same
US8067380B2 (en) * 2005-12-19 2011-11-29 Industrial Technology Research Institute Glutathione-based delivery system

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965406A (en) * 1984-06-07 1999-10-12 Seragen, Inc. Recombinant DNAS encoding three-part hybrid proteins
US6613882B1 (en) * 1997-07-18 2003-09-02 Institut Curie And Centre National De La Recherche Scientifique Chimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
WO2000037103A2 (en) * 1998-12-21 2000-06-29 Xavos Compounds for intracellular delivery of therapeutic moieties to nerve cells
WO2000046384A1 (en) * 1999-02-08 2000-08-10 University Of Maryland, Baltimore Nucleic acid uptake and release vehicle
US20020098999A1 (en) * 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
WO2004069870A2 (en) * 2003-02-10 2004-08-19 To-Bbb Holding B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
WO2005054279A1 (en) * 2003-11-21 2005-06-16 Orthogen Ag Delivery peptides, their constructs with active agents and use
US20070141133A1 (en) * 2005-12-19 2007-06-21 Industrial Technology Research Institute Glutathione based delivery system
EP1891962A1 (en) * 2005-12-19 2008-02-27 Industrial Technology Research Institute Glutathione based delivery system

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AWASTHI SANJAY ET AL: "Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): a novel link between G-protein and tyrosine kinase signaling and drug resistance.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 20 SEP 2003, vol. 106, no. 5, 20 September 2003 (2003-09-20), pages 635 - 646, XP002507012, ISSN: 0020-7136 *
BICKLEY JAMIE F ET AL: "Reactions of some cyclopentenones with selected cysteine derivatives and biological activities of the product thioethers.", BIOORGANIC & MEDICINAL CHEMISTRY 15 JUN 2004, vol. 12, no. 12, 15 June 2004 (2004-06-15), pages 3221 - 3227, XP002506716, ISSN: 0968-0896 *
CHADWICK D E ET AL: "CYTOTOXICITY OF A RECOMBINANT DIPHTHERIA TOXIN-GRANULOCYTE COLONY-STIMULATING FACTOR FUSION PROTEIN ON HUMAN LEUKEMIC BLAST CELLS", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 11, no. 3/04, 1 January 1993 (1993-01-01), pages 249 - 262, XP000611501, ISSN: 1042-8194 *
DUZGUNES N ET AL: "LIPOSOME-MEDIATED DELIVERY OF ANTIVIRAL AGENTS TO HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CELLS", MOLECULAR MEMBRANE BIOLOGY, TAYLOR AND FRANCIS, GB, vol. 16, no. 1, 1 January 1999 (1999-01-01), pages 111 - 118, XP008043323, ISSN: 0968-7688 *
GAILLARD ET AL: "A novel opportunity for targeted drug delivery to the brain", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 116, no. 2, 28 November 2006 (2006-11-28), pages e60 - e62, XP005794311, ISSN: 0168-3659 *
GAILLARD P J ET AL: "Targeted delivery across the blood-brain barrier", EXPERT OPINION ON DRUG DELIVERY, ASHLEY PUBLICATIONS, XX, vol. 2, no. 2, 1 January 2005 (2005-01-01), pages 299 - 309, XP008086757, ISSN: 1742-5247 *
GAILLARD PIETER J ET AL: "DIPHTHERIA TOXIN RECEPTOR-TARGETED BRAIN DRUG DELIVERY", INTERNATIONAL CONGRESS SERIES, EXCERPTA MEDICA, AMSTERDAM, vol. 1277, 1 January 2005 (2005-01-01), pages 185 - 198, XP009078687, ISSN: 0531-5131 *
HOLLIDAY J ET AL: "INHIBITION OF HERPES SIMPLEX VIRUS TYPES 1 AND 2 REPLICATION IN VITRO BY MERCURITHIO ANALOGS OF DEOXYURIDINE", ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, vol. 16, no. 2, 1 September 1991 (1991-09-01), pages 197 - 203, XP000925125, ISSN: 0166-3542 *
LEMAITRE M ET AL: "SPECIFIC ANTIVIRAL ACTIVITY OF A POLY(L-LYSINE)-CONJUGATED OLIGODEOXYRIBONUCLEOTIDE SEQUENCE COMPLEMENTARY TO VESICULAR STOMATITIS VIRUS N PROTEIN MRNA INITIATION SITE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, vol. 84, 1 February 1987 (1987-02-01), pages 648 - 652, XP002066265, ISSN: 0027-8424 *
LETSINGER R L ET AL: "CHOLESTERYL-CONJUGATED OLIGONUCLEOTIDES: SYNTHESIS, PROPERTIES, ANDACTIVITY AS INHIBITORS OF REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS IN CELL CULTURE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, vol. 86, no. 17, 1 September 1989 (1989-09-01), pages 6553 - 6556, XP000564447, ISSN: 0027-8424 *
VISSER C C ET AL: "Targeting liposomes with protein drugs to the blood-brain barrier in vitro", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 25, no. 2-3, 1 June 2005 (2005-06-01), pages 299 - 305, XP004903828, ISSN: 0928-0987 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102172348A (en) * 2011-02-12 2011-09-07 李春娟 Solid oseltamivir phosphate medicinal composition

Also Published As

Publication number Publication date
US20100129437A1 (en) 2010-05-27
WO2008118013A2 (en) 2008-10-02
TW200900081A (en) 2009-01-01
EP2125024B1 (en) 2013-02-13
PL2308514T3 (en) 2013-11-29
DK2308514T3 (en) 2013-09-02
ES2426684T3 (en) 2013-10-24
CY1114116T1 (en) 2016-07-27
HRP20130547T1 (en) 2013-08-31
SI2308514T1 (en) 2013-09-30
EP2308514B1 (en) 2013-06-05
PT2308514E (en) 2013-09-06
US20200390794A1 (en) 2020-12-17
US20130216612A1 (en) 2013-08-22
EP2308514A3 (en) 2011-04-20
EP2125024A2 (en) 2009-12-02
TW201417832A (en) 2014-05-16
TWI434699B (en) 2014-04-21
TWI537005B (en) 2016-06-11
US20150290234A1 (en) 2015-10-15
EP2308514A2 (en) 2011-04-13

Similar Documents

Publication Publication Date Title
WO2008118013A3 (en) Targeted intracellular delivery of antiviral agents
WO2010095940A3 (en) Glutathione-based drug delivery system
Dirin et al. Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides
Crooke Antisense strategies
WO2009045536A3 (en) Receptor targeted oligonucleotides
ES2556128T3 (en) Internally segmented small interfering RNA
Sasso et al. The progress and promise of RNA medicine─ an arsenal of targeted treatments
ES2574204T3 (en) Organic compositions to treat diseases related to beta-ENaC
Wacheck et al. Antisense molecules for targeted cancer therapy
WO2009009441A3 (en) Self-assembling complex for targeting chemical agents to cells
Wagner Biomaterials in RNAi therapeutics: quo vadis?
Thomas et al. Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models
JP2012521358A5 (en)
WO2007089607A3 (en) Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
WO2007131238A8 (en) Compounds and methods for modulating expression apob
WO2012170957A8 (en) Retinoid-liposomes for enhancing modulation of hsp47 expression
JP2018530530A5 (en)
Akhtar Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics
WO2013101983A3 (en) Targeted self-assembly 0f functionalized carbon nanotubes on tumors
WO2008054826A3 (en) Pathotropic targeted gene delivery system for cancer and other disorders
Grijalvo et al. Oligonucleotide delivery: a patent review (2010–2013)
Villalobos et al. Stability and immunogenicity properties of the gene-silencing polypurine reverse Hoogsteen hairpins
Scaggiante et al. Aptamers as targeting delivery devices or anti-cancer drugs for fighting tumors
WO2011034583A3 (en) Inhibition of endosomal toll-like receptor activation
Anwar et al. Enhancing the effectiveness of oligonucleotide therapeutics using cell-penetrating peptide conjugation, chemical modification, and carrier-based delivery strategies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08723917

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12532788

Country of ref document: US

Ref document number: 2008723917

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE